These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33065780)

  • 1. Effect of evolocumab on the progression and stability of atherosclerotic plaques as evaluated by grayscale and iMAP-IVUS.
    Kong Q; Liu M; Li Y; Zhu Q; Su G
    Ann Palliat Med; 2020 Sep; 9(5):3078-3088. PubMed ID: 33065780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
    Liang D; Li C; Tu Y; Li Z; Zhang M
    Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Evolocumab on Coronary Plaque Composition.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
    J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. THE EFFECT OF EVOLOCUMAB ALONE AND IN COMBINATION WITH ATORVASTATIN ON LIPID PROFILE.
    Saud AH; Ali NAJ; Gali FY; Hadi NR
    Wiad Lek; 2021; 74(12):3184-3187. PubMed ID: 35058387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression.
    Saud A; Ali N; Gali F; Qassam H; Hadi NR
    J Med Life; 2023 May; 16(5):759-765. PubMed ID: 37520489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
    Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ
    JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
    Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
    N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
    Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice.
    Pouwer MG; Pieterman EJ; Worms N; Keijzer N; Jukema JW; Gromada J; Gusarova V; Princen HMG
    J Lipid Res; 2020 Mar; 61(3):365-375. PubMed ID: 31843957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
    Yano H; Horinaka S; Ishimitsu T
    J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
    J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
    Watts GF; Chan DC; Somaratne R; Wasserman SM; Scott R; Marcovina SM; Barrett PHR
    Eur Heart J; 2018 Jul; 39(27):2577-2585. PubMed ID: 29566128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolocumab: Considerations for the Management of Hyperlipidemia.
    Wiggins BS; Senfield J; Kassahun H; Lira A; Somaratne R
    Curr Atheroscler Rep; 2018 Mar; 20(4):17. PubMed ID: 29511875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
    Watts GF; Chan DC; Dent R; Somaratne R; Wasserman SM; Scott R; Burrows S; R Barrett PH
    Circulation; 2017 Jan; 135(4):338-351. PubMed ID: 27941065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
    Rosenson RS; Jacobson TA; Preiss D; Djedjos CS; Dent R; Bridges I; Miller M
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):305-13. PubMed ID: 27240673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC; Watts GF; Somaratne R; Wasserman SM; Scott R; Barrett PHR
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.